Human Genome Sciences ( HGSI - news - people ) to fail.

FORBES: Health Care

Venter himself founded Human Genome Sciences (nasdaq: HGSI - news - people ).

FORBES: The DNA Of Capitalism

Human Genome Sciences ( HGSI - news - people ) was founded in the early 1990s by William Haseltine, a former Harvard researcher.

FORBES: Health Care

Human Genome Sciences (nasdaq: HGSI - news - people ) is developing a drug, Albuferon, a combination of the human protein albumin and interferon.

FORBES: Saving Your Liver

McDonald suggests one likely target: Albuferon, an interferon drug for hepatitis C now in phase 2 trials that belongs to Human Genome Sciences (nasdaq: HGSI - news - people ).

FORBES: Gilead's Half-Empty Pipeline

Under the leadership of genomics pioneer William Haseltine , Human Genome Sciences (nasdaq: HGSI - news - people ) has spent hundreds of millions of dollars over about a decade to develop drugs.

FORBES: Genomics Pioneer Takes On Anthrax

Among components of that ETF with the weakest showing for the week were shares of Human Genome Sciences ( HGSI), lower by about 5.9%, and shares of Enzon Pharmaceuticals ( ENZN), lower by about 3.8% on the week.

FORBES: Banner Week For Junior Gold Miners And Regional Banks, Bad One For Biotech ETFs

Human Genome Sciences (nsadaq: HGSI - news - people ) has several drugs derived from genes in clinical trials, and Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) has one, plus several drugs it acquired when it bought other companies.

FORBES: Biotech Royalty's Tarnished Crown

In the five years since Lander and Broad had their first talk, companies that aimed to make money off the genome such as Human Genome Sciences (nasdaq: HGSI - news - people ) and Celera Genomics (nyse: CRA - news - people ) have seen their stock prices plummet by more than 80%.

FORBES: Billionaire Broad Gives $100M To Gene Research